Want to see GH full AI Analyst Report?
GH Stock Chart & Stats
$147.33
-$1.86(-1.26%)
At close: 4:00 PM EDT
$147.33
-$1.86(-1.26%)
Day’s Range― - ―
52-Week Range$43.66 - $176.58
Previous Close$144.39
Volume1.29M
Average Volume (3M)2.92M
Market Cap
$21.74B
Enterprise Value$20.58K
Total Cash (Recent Filing)$1.05B
Total Debt (Recent Filing)$1.70B
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Oct 29, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.49
Shares Outstanding134,196,170
10 Day Avg. Volume1,760,827
30 Day Avg. Volume2,920,009
Financial Highlights & Ratios
PEG Ratio4.56
Price to Book (P/B)-128.95
Price to Sales (P/S)13.04
P/FCF Ratio-54.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$188.26Price Target Upside27.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)-2.88
Revenue Forecast (FY)$1.35B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & GuidanceSustained high-single to mid-double-digit revenue growth and a raised full-year guide indicate broad commercial adoption across Oncology, Screening and Biopharma. Durable top-line momentum supports scale economies, partner leverage in trials and continued reinvestment to extend market reach over the next 2–6 months.
High Gross Margin & Cost CutsA ~65%+ gross margin base plus identifiable, announced cost-per-test reductions from platform migration and a new Shield workflow create durable margin resilience as volumes scale. Lower COGS improves unit economics for Screening and preserves cash runway while the company commercializes higher-volume offerings.
Regulatory & Commercial MoatGuideline inclusion and major payer coverage are structural advantages that materially ease clinician adoption and patient access. Combined with demonstrated Shield volume traction, these durable commercial wins lower adoption friction and support long-term revenue capture in population screening markets.
Bears Say
High Leverage & Negative EquityA sizable debt load and negative equity materially constrain financial flexibility. Over the medium term this increases refinancing and covenant risk, limits capacity for opportunistic M&A or aggressive buybacks, and raises dependence on capital markets or partner financing while scaling Screening.
Continued Free Cash Flow BurnOngoing, sizable FCF burn requires the company to continue funding operations and capex externally in the near term. Persistent negative cash generation limits optionality, heightens dilution or debt needs, and makes execution on cost reductions and reimbursement outcomes essential to achieve cash‑flow breakeven by management's target.
Reimbursement & Pricing UncertaintyKey reimbursement decisions and program timings are unsettled, meaning realized ASP uplifts and Medicare coverage could be delayed. For durable profitability this risk matters: slow payer adoption or unfavorable terms would compress long-term revenue per test and slow the cash generation implied by current volume growth.
Guardant Health News
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $43.66 and its highest was $176.58 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $21.74B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Oct 29, 2026 which is in 84 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Jul 30, 2026. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.762 by -$0.138.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.76.
How many shares outstanding does Guardant Health have?
Guardant Health has 134,196,170 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.762. Following the earnings report the stock price went up 6.328%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$188.26 (27.78% Upside)
$188.26 (27.78% Upside)
Blogger Sentiment
Bullish
GH Sentiment 78%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 808.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $94.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
223.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.48%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
GH Company Deck
GH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum: broad-based, high-double-digit revenue and volume growth, major FDA approvals (Guardant360 Liquid CDx and a higher-throughput Shield workflow), guideline inclusion and a major payer (UnitedHealth) coverage decision for Shield, record Biopharma results, meaningful margin and cost-per-test improvement initiatives, and expanded commercial reach. Offsetting these positives are elevated operating expenses and investments (S&M and CapEx) to scale Screening, a modest adjusted EBITDA loss and increased free cash flow burn, and outstanding reimbursement/pricing uncertainties (ADLT timing, MolDX/Reveal coverage, USPSTF). On balance, the positive commercial, regulatory and margin trends materially outweigh the near-term cost and reimbursement risks, though execution and payer outcomes remain key near-term sensitivities.View all GH earnings summariesGH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
GH Stock 12 Month Forecast
Average Price Target
$188.26
▲(27.78% Upside)
Technical Analysis
Ownership Overview
3.29% Insiders
34.35% Mutual Funds
2.24% Other Institutional Investors
45.77% Public Companies and
Individual Investors